Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis
Source: SeekingAlpha
2025-04-29 14:42:30 ET
More on Alumis, Acelyrin, etc.
- Alumis: Biotech's Stock Gains >100% In A Month - But Risk Of Failure Is High
- Acelyrin: Potential Buyout Led By Concentra Biosciences
- Alumis, ACELYRIN amend proposed merger pact
- Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes
- Historical earnings data for Alumis
Read the full article on Seeking Alpha
For further details see:
Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis
ACELYRIN INC.
NASDAQ: SLRN
SLRN Trading
1.32% G/L:
$2.27 Last:
4,076,542 Volume:
$2.24 Open:
SLRN Latest News
SLRN Stock Data
$229,164,788
70,869,463
N/A
17
N/A
Biotechnology & Life Sciences
Healthcare
US
